Gyre Therapeutics

GYRE · NASDAQ

$6.17+$0.05 (+0.82%)TodayMarket closed · Oct 21, 4:10 AM ET

Prev close $6.12

GYRE analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Feb 9, 2026

Bull case

Gyre Therapeutics Inc is well-positioned for growth due to its strategic acquisition of generic nintedanib, which enhances its capital base and operational capabilities during challenging market conditions. This move solidifies Gyre's leadership in the idiopathic pulmonary fibrosis (IPF) space while broadening its portfolio of therapies targeting both lung and liver fibrosis. Additionally, the company demonstrates a diverse pipeline with multiple drug candidates, including those in China, indicating a robust foundation for future revenue expansion.

Bear case

Gyre Therapeutics Inc is experiencing a negative financial outlook primarily due to depressed forward multiples attributed to current market volatility, which reflects broader concerns in the pharmaceutical sector. Additionally, the company’s reliance on commercial sales of certain drugs, such as pirfenidone in China, is undercut by the absence of growth potential, as revenue generation has plateaued. Furthermore, significant cash burn challenges are anticipated depending on the progress of development programs, which could exacerbate financial strain without reliable erratic offsetting from collaborative revenue streams.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.